Anuh Pharma Q4 Results 2026 Preview, Earnings & Revenue Projections

March 24, 2026
Posted by: Neeraj Pandey
Category: News

Anuh Pharma latest news: Anuh Pharma Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Anuh Pharma was listed on the National Stock Exchange (NSE) on 20-Dec-2024. Anuh Pharma share has its face value of 5 per share, and its NSE symbol is ANUHPHR. The company operates in the Healthcare sector and primarily belongs to the Active Pharmaceutical Ingredients industry.

Table of Contents

Anuh Pharma Q4 Results 2026 Preview

Anuh Pharma Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-14% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 11-16% YoY.
EBITDA to rise 10-15%.
Anuh Pharma is expected to show Moderate Growth Expected in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Anuh Pharma Share Performance

Over the past six months, Anuh Pharma share price has Up by 20% to 75.31.
Moreover, over the past year, the stock has Up by 35%
Despite this weak short-term performance, Anuh Pharma stock has delivered a financially sound 170% return over the past 5 years.
As of today, 20-03-2026, the Anuh Pharma share price is trading at 75.31 per share.

Key Factors to Watch for Anuh Pharma Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Active Pharmaceutical Ingredients industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

Visit Univest app or website to check more Anuh Pharma latest news to make an informed investment decision.

About Anuh Pharma

Anuh Pharma manufactures active pharmaceutical ingredients and specialty chemicals exported to pharmaceutical companies globally.

Visit Univest app or website to check more Anuh Pharma latest news to make an informed investment decision.

Final Thoughts

Anuh Pharma is gear up to announce its Q4 FY26 results. Analysts expect 10-14% revenue growth, a 11-16% rise in PAT, and a 10-15% rise in EBITDA. Anuh Pharma focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Anuh Pharma Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

AMD Industries Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Ambika Cotton Mills Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Amagi Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Alphageo Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

Almondz Global Q4 Results Preview: Earnings Growth, Key Expectations & Outlook

News Q4 results expectations

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.